Drug Profile
Recilisib
Alternative Names: Ex-RAD; ON 01210.Na; ON-01210; ON-01210-Na; Recilisib sodiumLatest Information Update: 21 May 2018
Price :
$50
*
At a glance
- Originator Onconova Therapeutics
- Class Radioprotectives; Small molecules; Sulfonamides
- Mechanism of Action Apoptosis inhibitors; Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Acute radiation syndrome
Most Recent Events
- 21 May 2018 Recilisib is still in phase I trials for Acute Radiation Syndrome in USA (PO) (SC) (Onconova Therapeutics pipeline, May-2018)
- 28 Apr 2018 No recent reports of development identified for phase-I development in Acute-radiation-syndrome in USA (PO, Liquid)
- 28 Apr 2018 No recent reports of development identified for phase-I development in Acute-radiation-syndrome in USA (SC, Injection)